EYES
Income statement / Annual
Last year (2021), Second Sight Medical Products, Inc.'s total revenue was -$130,000.00,
a decrease of 74.00% from the previous year.
In 2021, Second Sight Medical Products, Inc.'s net income was -$8.93 M.
See Second Sight Medical Products, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
Operating Revenue |
-$130,000.00
|
-$500,000.00
|
$3.38 M
|
$6.90 M
|
$7.96 M
|
$3.99 M
|
$8.95 M
|
$3.40 M
|
$1.56 M
|
$1.37 M
|
Cost of Revenue |
$0.00 |
$0.00 |
$2.15 M |
$4.89 M |
$5.12 M |
$10.08 M |
$5.29 M |
$3.56 M |
$5.63 M |
$4.40 M |
Gross Profit |
-$130,000.00 |
-$500,000.00 |
$1.23 M |
$2.01 M |
$2.85 M |
-$6.09 M |
$3.66 M |
-$160,283.00 |
-$4.06 M |
-$3.03 M |
Gross Profit Ratio |
1 |
1 |
0.36 |
0.29 |
0.36 |
-1.53 |
0.41 |
-0.05 |
-2.6 |
-2.22 |
Research and Development
Expenses |
$2.37 M
|
$4.84 M
|
$13.14 M
|
$10.01 M
|
$7.89 M
|
$5.35 M
|
$3.04 M
|
$5.04 M
|
$3.25 M
|
$3.05 M
|
General & Administrative
Expenses |
$6.32 M
|
$5.94 M
|
$9.23 M
|
$10.69 M
|
$10.93 M
|
$10.08 M
|
$8.22 M
|
$6.57 M
|
$4.17 M
|
$4.03 M
|
Selling & Marketing
Expenses |
$0.00
|
$701,000.00
|
$6.10 M
|
$11.34 M
|
$9.57 M
|
$8.99 M
|
$8.94 M
|
$6.84 M
|
$3.30 M
|
$2.19 M
|
Selling, General &
Administrative Expenses |
$6.32 M
|
$6.64 M
|
$15.33 M
|
$22.03 M
|
$20.50 M
|
$19.07 M
|
$17.16 M
|
$13.41 M
|
$7.47 M
|
$6.22 M
|
Other Expenses |
$378,000.00 |
$1.69 M |
$3.35 M |
$4.60 M |
$3.06 M |
$2.70 M |
$3.51 M |
$2.62 M |
$3.22 M |
$3.73 M |
Operating Expenses |
$9.06 M |
$13.17 M |
$31.82 M |
$36.63 M |
$31.46 M |
$27.12 M |
$23.70 M |
$21.07 M |
$13.93 M |
$12.99 M |
Cost And Expenses |
$8.93 M |
$12.67 M |
$33.98 M |
$41.52 M |
$36.57 M |
$37.20 M |
$29.00 M |
$24.63 M |
$19.56 M |
$17.39 M |
Interest Income |
$12,000.00 |
$16,000.00 |
$362,000.00 |
$86,000.00 |
$93,000.00 |
$31,000.00 |
$2,000.00 |
$9,108.00 |
$7,454.00 |
$7,512.00 |
Interest Expense |
$12,000.00 |
$16,000.00 |
$362,000.00 |
$86,000.00 |
$93,000.00 |
$31,000.00 |
$29,000.00 |
$7.03 M |
$5.01 M |
$267,031.00 |
Depreciation &
Amortization |
$70,000.00
|
$164,000.00
|
$397,000.00
|
$435,000.00
|
$457,000.00
|
$432,000.00
|
$335,000.00
|
$279,179.00
|
$315,770.00
|
$324,712.00
|
EBITDA |
-$8.84 M
|
-$14.70 M
|
-$32.83 M
|
-$34.57 M
|
-$27.97 M
|
-$32.72 M
|
-$19.65 M
|
-$27.89 M
|
-$17.64 M
|
-$15.69 M
|
EBITDA Ratio |
67.99 |
29.4 |
-9.72 |
-5.01 |
-3.51 |
-8.21 |
-2.2 |
-8.21 |
-11.27 |
-11.47 |
Operating Income Ratio
|
68.53
|
29.79
|
-10.05
|
-5.1
|
-3.59
|
-8.33
|
-2.24
|
-6.25
|
-11.5
|
-11.72
|
Total Other
Income/Expenses Net |
-$12,000.00
|
$16,000.00
|
$362,000.00
|
$586,000.00
|
$93,000.00
|
$31,000.00
|
$29,000.00
|
-$13.97 M
|
-$4.97 M
|
-$257,744.00
|
Income Before Tax |
-$8.92 M |
-$14.88 M |
-$33.59 M |
-$35.09 M |
-$28.52 M |
-$33.18 M |
-$20.02 M |
-$35.20 M |
-$22.97 M |
-$16.28 M |
Income Before Tax Ratio
|
68.62
|
29.76
|
-9.94
|
-5.09
|
-3.58
|
-8.33
|
-2.24
|
-10.36
|
-14.68
|
-11.91
|
Income Tax Expense |
$12,000.00 |
$32,000.00 |
$724,000.00 |
$172,000.00 |
$186,000.00 |
$62,000.00 |
$58,000.00 |
-$6.93 M |
$42,222.00 |
$9,287.00 |
Net Income |
-$8.93 M |
-$14.88 M |
-$33.59 M |
-$35.09 M |
-$28.52 M |
-$33.18 M |
-$20.02 M |
-$35.20 M |
-$22.97 M |
-$16.28 M |
Net Income Ratio |
68.72 |
29.76 |
-9.94 |
-5.09 |
-3.58 |
-8.33 |
-2.24 |
-10.36 |
-14.68 |
-11.91 |
EPS |
-0.82 |
-2.17 |
-54.81 |
-12.69 |
-12.64 |
-20.13 |
-12.37 |
-30.94 |
-14.61 |
-10.35 |
EPS Diluted |
-0.82 |
-2.17 |
-54.81 |
-12.69 |
-12.64 |
-20.13 |
-12.37 |
-30.94 |
-14.61 |
-10.35 |
Weighted Average Shares
Out |
$10.94 M
|
$6.86 M
|
$612,833.00
|
$2.77 M
|
$2.26 M
|
$1.65 M
|
$1.62 M
|
$1.14 M
|
$1.57 M
|
$1.57 M
|
Weighted Average Shares
Out Diluted |
$10.94 M
|
$6.86 M
|
$612,833.00
|
$2.77 M
|
$2.26 M
|
$1.65 M
|
$1.62 M
|
$1.14 M
|
$1.57 M
|
$1.57 M
|
Link |
|
|
|
|
|
|
|
|
|
|